Your browser doesn't support javascript.
loading
[DICER1 constitutional pathogenic variant syndrome: Where are we in 2019?] / Syndrome associé aux variants pathogènes constitutionnels de DICER1 : Où en sommes-nous en 2019 ?
Réguerre, Yves; Golmard, Lisa; Brisse, Hervé J; Oliver Petit, Isabelle; Savagner, Frédérique; Boudjemaa, Sabah; Gauthier-Villars, Marion; Rod, Julien; Fresneau, Brice; Orbach, Daniel.
Afiliação
  • Réguerre Y; Centre Hospitalo-Universitaire de Saint Denis, service d'oncologie et d'hématologie pédiatrique, 97400 La Réunion, France. Electronic address: yves.reguerre@chu-reunion.fr.
  • Golmard L; Institut Curie, service de génétique, 75005 Paris, France.
  • Brisse HJ; Institut Curie, université Paris Sciences et Lettres, département d'imagerie, 26, rue d'Ulm Paris, 75005 Paris, France.
  • Oliver Petit I; Hôpital des enfants, unité d'endocrinologie, génétique, maladies osseuses et gynécologie de l'enfant, TSA 70034, 31059 Toulouse Cedex, France.
  • Savagner F; Hôpital Purpan, biologie moléculaire endocrinienne, service de biochimie, IFB, TSA 40031, 31059 Toulouse cedex, France.
  • Boudjemaa S; Hôpital d'enfants Armand Trousseau-assistance publique, service d'anatomie et de cytologie pathologiques, 75012 Paris, France.
  • Gauthier-Villars M; Institut Curie, service de génétique oncologique, 75005 Paris, France.
  • Rod J; Université de Caen, département de chirurgie pédiatrique, 14000 Caen, France; Université de Caen Basse-Normandie, UFR Médecine, 14000 Caen, France.
  • Fresneau B; Université Paris-Saclay, Gustave Roussy, département d'oncologie pédiatrique, 94805 Villejuif, France; Inserm, université Paris-Sud Paris-Saclay, CESP, 94805 Villejuif, France.
  • Orbach D; Institut Curie, PSL université, Centre oncologie SIREDO (Soins, innovation recherche en oncologie de l'enfant, l'adolescent et du jeune adulte), 75005 Paris, France.
Bull Cancer ; 106(12): 1177-1189, 2019 Dec.
Article em Fr | MEDLINE | ID: mdl-31610911
Inactivating germline pathogenic variants of the DICER1 gene are responsible for a spectrum of rare diseases, which expanded a lot in recent years. The constitution of an U.S. registry with these patients and their families as well as the registration of patients in European databases of rare tumors helped to better identify diseases encountered in this syndrome but also to study its pathophysiology (major role in miRNA maturation and recently discovered functions, e.g. in genome integrity maintenance). Most encountered disorders are pediatric malignancies, mainly the pulmonary pneumoblastoma and Sertoli-Leydig tumours. However, benign pathologies such as thyroid goiters, cystic nephromas or pulmonary cystic lesions are also frequently reported. Homogeneous guidelines regimens written by the European groups working on very rare pediatric tumors are proposed but it is important to underscore that they rely on rare scientific data; therefore overall consensus remains precarious. The genetic counseling to families is still difficult due to the large observed spectrum of tumors and the incomplete penetrance. In this article, the authors update current knowledge on the DICER1 syndrome.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Raras / Ribonuclease III / RNA Helicases DEAD-box / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans Idioma: Fr Revista: Bull Cancer Ano de publicação: 2019 Tipo de documento: Article País de publicação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Raras / Ribonuclease III / RNA Helicases DEAD-box / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans Idioma: Fr Revista: Bull Cancer Ano de publicação: 2019 Tipo de documento: Article País de publicação: França